Interleukin-12, and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis

Journal of Clinical Investigation

Volumn 101, Issue 6, 1998, Pages 1441-1452

  Coughlin, Christina M ^d   Salhany, Kevin E ^d   Wysocka, Maria ^a   Aruga, Etsuko ^b   Kurzawa, Holly ^d   Chang, Alfred E ^c   Hunter, Christopher A ^d   Fox, Jonathan C ^d   Trinchieri, Giorgio ^a   Lee, William M F ^a,d,e  

^a WISTAR INSTITUTE   (United States)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CRB 663 ^*  (United States)

Author keywords

Cytokine; Immunotherapy; Interleukin 12; Interleukin 18; Tumor angiogenesis

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12;

ADOLESCENT; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

EID: 0032521153     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI1555     Document Type: Article

References (40)

1. Martinotti, A., A. Stoppacciaro, M. Vagliani, C. Melani. F. Spreafico, M. Wysocka, G. Parmiani, G. Trinchieri, and M. Colombo. 1995. CD4 T cells inhibit in vivo CD8-mediated immune response against a murine colon carcinoma transduced with IL-12 genes. Eur. J. Immunol. 25:137-146.
2. Colombo, M.P., M. Vagliani, F. Spreafico, M. Parenza, C. Chiodoni, C. Melani, and A. Stoppacciaro. 1996. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res. 56:2531-2534.
3. Tahara, H., L. Zitvogel, W.J. Storkus, H.J. Zeh III, T.J. McKinney. H. Schreiber, U. Gubler, P.D. Robbins, and M.T. Lotze. 1995. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J. Immunol. 154:6466-6474.
4. Tahara, H., H.J. Zeh III, W.J. Storkus. I. Pappo, S.C. Watkins, U. Gubler, S. Wolf, P.D. Robbins, and M.T. Lotze. 1994. Fibroblasts genetically engineered to secrete IL-12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res. 54:182-189.
5. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251-276.
6. + T cells through IL-12 produced by Listeria-induced macrophages. Science. 260:547-550.
7. Yu, W.G., N. Yamamoto, H. Takenaka, J. Mu, X.G. Tai, J.P. Zou, M. Ogaa, T. Tsutsui, S. Herrmann, H. Fujiwara, and T. Hamoaka. 1996. Molecular mechanisms underlying IFN-gamma mediated growth inhibition induced during tumor immunotherapy with IL-12. Int. Immunol. 8:855-865.
8. Tsung, K., J.B. Meko, G.R. Peplinski, Y.L. Tsung, and J.A. Norton. 1997. IL-12 induces TH1-directed antitumor response. J. Immunol. 158:3359-3365.
9. Bloom, E.T., and J.A. Horvath. 1994. Cellular and molecular mechanisms of the IL-12-induced increase in allospecific murine cytolytic T cell activity. J. Immunol. 152:4242-4254.
10. Nastala, C.L., H.D. Edington, T.G. McKinney, H. Tahara, M.A. Nalesnik, M.J. Brunda, M.K. Gately, S.F. Wolf, R.D. Schreiber, W.J. Storkus, and M.T. Lotze. 1994, Recombinant IL-12 administration induces tumor regression in association with IFN-γ production. J. Immunol. 153:1697-1706.
11. Coughlin, C.M., M. Wysocka, H.L. Kurzawa, W.M.F. Lee, G. Trinchieri, and S.L. Eck. 1995. B7-1 and interleukin-12 synergistically induce effective antitumor immunity. Cancer Res. 55:4980-4987.
12. Coughlin, C.M., M. Wysocka, G.T. Trinchieri, and W.M.F. Lee. 1997. The effect of interleukin 12 desensitization on the antitumor efficacy of interleukin 12. Cancer Res. 57:2460-2467.
13. Car, B.D., V.M. Eng, B. Schnyder, M. LeHir, A.N. Shakov, G. Woerly, S. Huang, M. Aguet,T.D. Andersen, and B. Ryffel. 1995. Role of IFN-γ in interleukin 12-induced pathology in mice. Am. J. Pathol. 147:1693-1707.
14. Boehm. U., T. Klamp. M. Groot, and J.C. Howard. 1997. Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795.
15. Revel, M., and J. Chebath. 1986. Interferon-activated aenes. Trends Biochem. Sci. 11:166-170.
16. Xie, Q.W., R. Whisnant, and C. Nathan. 1993. Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide. J. Exp. Med. 177:1779-1784.
17. Voest, E.E., B.M. Kenyon, M.S. O'Reilly, G. Truitt, R.J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by IL-12. J. Natl. Cancer Inst. 87:581-586.
18. Sgadari, C., A.L. Angiolillo, and G, Tosato. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10. Blood. 87:3877-3882.
19. Watanabe, M., K.L. McCormick, K. Volker. J.R. Ortaldo, J.M. Wigginton, M.J. Brunda, R.H. Wiltrout, and W.E. Fogler. 1997. Regulation of local host-mediated antitumor mechanisms by cytokines. Am. J. Pathol. 150:1869-1880.
20. Majewski, S., M. Marczak, A. Szmurlo, S. Jablonska, and W. Bollag. 1996. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J. Investig. Dermatol. 106:1114-1118.
21. Ushio, S., M. Namba, T. Okura, K. Hattori, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, et al. 1996. Cloning of the cDNA for human interferon-gamma-inducing factor (IGIF). expression in E. coli, and studies on the biologic activities of the protein. J. Immunol. 156:4274-4279.
22. Okamura, H., H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature. 378:88-91.
23. Micallef, M.J., T. Ohtsuki, K. Kohno, F. Tanabe, S. Ushio, M. Namba, T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, et al. 1996. Interferon-gamma inducing factor enhances Th1 cytokine production by stimulated human T cells: synergism with interleukin 12 for interferon gamma production. Eur. J. Immunol. 26:1647-1651.
24. Tsutsui, H., K. Nakanishi, K. Matsui, K. Higashino, H. Okamura, Y. Miyazawa, and K. Kaneda, 1996. Interferon-γ-inducing factor (IGIF) upregulates Fas-ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 157:3967-3973.
25. Micallef, M.J., K. Yoshida, S. Kawai, T. Hanaya, K. Kohno, S. Arai. T. Tanimoto, K. Torigoe, M. Fujii, M. Ikeda, and M. Kurimoto. 1997. In vivo antitumor effects of murine interferon-g-inducing factor/interleukin 18 in mice bearing syngeneic Meth A sarcoma malignant ascites. Cancer Immunol. Immunother. 43:361-367.
26. Song, C.W., M.S. Kang, J.G. Rhee, and S.H. Levitt. 1994. Vascular damage and delayed cell death in tumors after hyperthermia. Br. J. Cancer. 41:309-312.
27. Baskar. S., S. Ostrand-Rosenherg, N. Nabavi, L.M. Nadler, G.J. Freeman, and L.H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA. 90:5687-5690.
28. Tan, J., C.A. Newton, J.Y. Djeu, D.E. Gutsch, A.E. Chang, N.S. Yang, T.W. Klein, and Y. Hua. 1996. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res. 56:3399-3403.
29. Abrams, J.S., M.G. Roncarolo, H. Yssel, G.J. Andersson, and J.E. Silver. 1992. Strategies of anti-cytokine monoclonal antibody development: immunoassay of interleukin-10 and interleukin-5 in clinical samples, Immunol. Rev. 127:5-24.
30. Wysocka, M., M. Kubin, L.Q. Vieira, L. Ozmen, G. Garotta, P. Scott, and G. Trinchieri. 1995. Interleukin-12 is required for interferon-g production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25: 672-676.
31. Kleinman, H.K., M.L. McGarvey, L.A. Liotta, P.G. Robey, K. Tryggvason, and G.R. Martin. 1982. Isolation and characterizalion of type IV procollagen. laminin, and heparin sulfate proteoglycan from the EHS sarcoma. Biochemistry. 21:6188-6193.
32. Passaniti, A., R.M. Taylor, R. Pili, R. Guo, P.V. Long, J.A. Haney, D.S. Grant, and G.R. Martin. 1992. A simple quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblastic growth factor. Lab. Invest. 67:519-528.
33. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364.
34. Folkman, J. 1997. Angiogenesis and angiogenesis inhibition: an overview. Exper. Suppl. (Basel). 79:1-8.
35. Yoshimoto, T., H. Okamura, Y. Tagawa, Y. Iwakura, and K. Nakanishi, 1997. Interleukin 18 together with interlcukin 12 inhibits IgE production by induction of interferon-gamma from activated B cells. Proc. Natl. Acad, Sci. USA. 94:3948-3953.
36. Cavallo, F., P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M.J. Brunda, M.P. Colombo, and G. Forni. 1997. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J. Natl. Cancer Inst. 89:1049-1058.
37. Angiolillo. A.L., C. Sgdari, D.D. Taub, F. Liao, J.M. Farber, H.K. Kleinmann, G.H. Reaman, and G. Tosato. 1995. Human interferon inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J. Exp. Med. 182:155-162.
38. Sgadari, C., J.M. Farber, A.L. Angiolillo, F. Liao, J. Teryua-Feldstein. P.R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood. 89: 2635-2643.
39. O'Reilly, M.S., L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, M. Moses, W.S. Lane, Y. Cao, E.H. Sage, and J. Folkman. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315-328.
40. O'Reilly, M.S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W.S. Lane, E. Flynn, J.R. Birkhad, B.R. Olsen, and J. Folkman. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277-285.